The initial finding of the overactive eCB status in human subjects with obesity led to the discovery of rimonabant, the first available CB1R antagonist/inverse agonist, for the treatment of obesity in humans. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.